Opus Genetics Business Summary

Opus Genetics, Inc. (NASDAQ: IRD) is a clinical-stage biopharmaceutical company specializing in the development of adeno-associated virus (AAV)-based gene therapies for rare inherited retinal diseases (IRDs). The company generates revenue primarily through strategic licensing agreements, R&D milestones, and royalty streams from its partnered commercial asset, phentolamine ophthalmic solution 0.75% (approved for pharmacologically induced mydriasis). Its business is bifurcated into two primary segments: a robust gene therapy pipeline targeting mutations such as LCA5, BEST1, and RHO, and a small-molecule platform focused on refractive disorders like presbyopia and low-light visual disturbances. Positioned as a specialized leader in the orphan ophthalmic space, Opus Genetics competes with broader biotech and gene therapy firms such as Alvotech (ALVO), Calliditas Therapeutics (CALT), Evotec (EVO), and AbCellera Biologics (ABCL), distinguishing itself through a high-density focus on ultra-rare retinal indications with significant unmet needs. The company’s leadership is anchored by CEO George Magrath, MD, MBA, a board-certified ophthalmologist with extensive CRO and clinical experience, and President Ben Yerxa, PhD, who co-founded the company and previously led the Foundation Fighting Blindness. The executive suite includes CFO Robert Gagnon, CTO Chris Ernst, and Chief Scientific and Development Officer Ash Jayagopal, PhD. The founding team also features Jason Menzo and world-renowned gene therapy pioneer Jean Bennett, MD, PhD, the visionary behind the first FDA-approved gene therapy for an inherited disease. Opus is backed by a sophisticated investor base including the Retinal Degeneration (RD) Fund, Adage Capital Management, Marshall Wace, and Trails Edge Capital Partners, reflecting strong institutional confidence in its multi-asset clinical trajectory and its 2024 merger-driven expansion.